| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 209,3 k € | -4.9% | 220,2 k € | +0.3% | 219,6 k € | -18.0% | 267,9 k € | +3.2% | 259,5 k € | +14.2% | 227,3 k € | -0.5% | 228,4 k € | -2.1% | 233,2 k € | -2.1% | 238,2 k € | +0.7% | 236,5 k € | -10.2% | 263,3 k € | -6.7% | 282,2 k € | +19.5% | 236,0 k € | +0.2% | 235,5 k € | |
| EBITDA | 206,7 k € | -5.4% | 218,6 k € | -0.1% | 218,7 k € | -17.5% | 265,0 k € | +2.1% | 259,5 k € | +14.6% | 226,4 k € | -0.5% | 227,6 k € | -2.0% | 232,3 k € | -2.0% | 237,2 k € | +0.7% | 235,5 k € | -10.2% | 262,3 k € | -6.7% | 281,2 k € | +19.4% | 235,5 k € | +0.2% | 234,9 k € | |
| Operating profit | 195,5 k € | -5.7% | 207,3 k € | -0.1% | 207,4 k € | -21.3% | 263,6 k € | +1.6% | 259,5 k € | +14.6% | 226,4 k € | -0.5% | 227,6 k € | -2.0% | 232,3 k € | -2.0% | 237,2 k € | +0.7% | 235,5 k € | -10.2% | 262,3 k € | -3.8% | 272,7 k € | +24.8% | 218,5 k € | -3.5% | 226,4 k € | |
| Profit/loss | 161,4 k € | +14.6% | 140,8 k € | -10.2% | 156,8 k € | -38.1% | 253,2 k € | -24.6% | 335,8 k € | +52.3% | 220,5 k € | +2.2% | 215,8 k € | +112.0% | 101,8 k € | +9.8% | 92,7 k € | +3.8% | 89,3 k € | -39.2% | 146,7 k € | +12.9% | 130,0 k € | -4.9% | 136,7 k € | +43.6% | 95,2 k € | |
| Equity | 1,3 M € | +2.1% | 1,3 M € | -12.4% | 1,4 M € | +12.3% | 1,3 M € | -20.7% | 1,6 M € | +26.5% | 1,3 M € | +21.1% | 1,0 M € | +26.0% | 831,4 k € | +13.9% | 729,6 k € | +14.6% | 636,9 k € | +16.3% | 547,7 k € | +36.6% | 400,9 k € | +35.5% | 295,9 k € | +85.8% | 159,2 k € | |
| Total assets | 2,6 M € | -1.1% | 2,6 M € | -0.2% | 2,6 M € | -0.9% | 2,7 M € | +4.0% | 2,6 M € | +0.6% | 2,5 M € | -0.8% | 2,6 M € | -0.3% | 2,6 M € | +0.1% | 2,6 M € | -0.1% | 2,6 M € | -0.3% | 2,6 M € | +0.1% | 2,6 M € | -0.3% | 2,6 M € | -0.3% | 2,6 M € | |
| Cash | 56,7 k € | +31.0% | 43,2 k € | -38.4% | 70,2 k € | -16.5% | 84,0 k € | +259.9% | 23,3 k € | +129.3% | 10,2 k € | -67.6% | 31,4 k € | -20.4% | 39,4 k € | +1325.0% | 2,8 k € | -45.2% | 5,0 k € | -88.8% | 44,9 k € | +379.1% | 9,4 k € | +17.5% | 8,0 k € | -53.2% | 17,0 k € | |
| Debts | 1,3 M € | -4.0% | 1,4 M € | +14.3% | 1,2 M € | -13.1% | 1,4 M € | +45.5% | 953,3 k € | -25.1% | 1,3 M € | -16.0% | 1,5 M € | -12.9% | 1,7 M € | -5.4% | 1,8 M € | -4.9% | 1,9 M € | -4.7% | 2,0 M € | -6.7% | 2,2 M € | -4.9% | 2,3 M € | -6.0% | 2,4 M € | |
Private limited company · Herent · incorporated on 03/08/2009
Private limited company profitable and well capitalised. Cash position rising (+31.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
MARKRI-FARMA is a Private limited company incorporated in 2009. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Herent.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette